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INTRODUCTION
Schizophrenia is a clinical syndrome of severe mental ill-
ness characterized by organized thinking processes, halluci-
nations, delusions, and functional deterioration (1). Schizo-
phrenia remains a diagnosis of exclusion, since none of its
clinical features are pathognomonic (2), and applicable bio-
chemical, neuroradiologic, physiologic, and psychological
tests lack the sensitivity and specificity required for a deci-
sive diagnosis. While numerous neuroanatomical, neuro-
physiological and neurochemical abnormalities have been
described for the brains of patients with schizophrenia, the
pathognomonic neurobiological mechanisms of the disorder
have not yet been determined. Family, twin, and adoption
studies indicate that there is a major heritable component
to schizophrenia (3). Recent progress in molecular biology,
neuroimaging, animal modeling, and genetics have signifi-
cantly enhanced efforts to understand schizophrenia. Genet-
ic studies have implicated several minor susceptibility loci,
however the clinical impact of these loci on the neurobiolo-
gy of schizophrenia is still unclear. In addition, researchers
have reported an association of the disease with a polymor-
phism in candidate genes, such as the dopamine D3 recep-
tor gene (4) and an expansion of trinucleotide repeats (5).
Apolipoprotein E (apoE) is found in plasma, where it has
an important role in the transport of cholesterol and the mod-
ulation of atherogenic lipoprotein metabolism (6). It is also
produced by astrocytes and oligodendrocytes in the central
nervous system, where its physiological role is less certain (7).
ApoE is suggested, however, to be involved in the transport
of cholesterol in myelin and neuronal membranes, and also
to play important roles in neuronal growth and central ner-
vous system response to injury (8). The gene for human APOE
is found on the long arm of chromosome 19 (19q13.2) (9)
and exists in three common allelic forms ( 2,  3, and  4).
These three alleles encode the main isoforms of apoE (E2,
E3, and E4), which differ by amino acid substitutions at
one or both of two sites, imparting distinctive physical and
biochemical properties to each isoform (10).
Recently, it has been established that the APOE 4 allele
is a risk factor for the development of Alzheimer’ s disease
(AD) (11), while the  2 allele has been implicated as a pro-
tective factor against the development of dementia in AD
(12). These genetic associations have led to many investiga-
tions on the role of APOE genotypes in other neuropsychi-
atric disorders. The association between APOE genotype and
schizophrenia was first reported in 1995 (13) and subsequent
studies on APOE genotype distribution in schizophrenia
have reported conflicting findings (14-21). We examined
the APOE genotype frequencies in Korean schizophrenic
patients in order to corroborate the potential association
between APOE genotypes and schizophrenia reported in
previous studies.
MATERIALS AND METHODS
Sixty inpatients with schizophrenia (39 males, 21 females,
mean age±SD:32.95±7.04 yr) at the Department of Psy-
chiatry, Chung-Ang University Hospital were selected for
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Apolipoprotein E Genotype in Korean Schizophrenic Patients
The apolipoprotein E (APOE) 4 allele is a known risk factor for the development
of Alzheimer’ s disease, however, an association of the APOE genotype with
schizophrenia is controversial. We investigated the association in 60 Korean
schizophrenic patients and 60 healthy controls. APOE genotypes were identified
by reverse hybridization-based line probe assay. There were significant differ-
ences in the distribution of APOE genotypes between schizophrenic patients and
controls. APOE 2 and  3 allele frequencies in schizophrenic patients were sig-
nificantly different from those in controls. Our results suggest that APOE alleles
seem to be operative in the pathogenesis of schizophrenic disorders.
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this study. All patients had a diagnosis of schizophrenia accord-
ing to DSM-IV criteria. Sixty healthy controls (30 males, 30
females, mean age±SD:35.04±8.93 yr) had undergone
diagnostic assessments and were devoid of psychiatric and
neurologic illnesses. The patients and controls were free of
diabetes, dyslipidemia, and history of cardiovascular disease.
APOE genotypes were examined by reverse hybridization-
based line probe assay (LiPA; INNO-LiPA APOE, Innogenet-
ics, Belgium) (22). Specific oligonucleotides were immobi-
lized at known locations on a membrane strip and were hy-
bridized under strictly controlled conditions with biotin-
labelled polymerase chain reaction (PCR) product. The hy-
brids formed are subsequently detected colorimetrically.
The LiPA was performed as described in the user manual
supplied. DNA was extracted from blood by a simple method
using proteinase K (23). Target DNA was amplified in a
PCR using the biotinylated primers. The PCR consisted of
30 cycles of 95℃ for 30 sec, 60℃ for 20 sec, and 72℃ for
20 sec, followed by a final cycle of 10 min at 72℃. After gel
analysis, PCR products would be denatured and hybridized
to membrane-bound capture probes, followed by a color detec-
tion step that involved the addition of a conjugate (strepta-
vidin) to which the enzyme alkaline phosphatase was bound.
Chromogenic substrates (5-bromo-4-chloro-3-indolyl phos-
phate and nitro blue tetrazolium) were added and converted
into an insoluble purple-blue product by the alkaline phos-
phatase. Interpretation of the banding pattern allowed dif-
ferentiation of APOE genotypes. Statistical analysis of APOE
genotype distributions and allele frequencies were performed
by the chi-square analysis and Fisher’ s exact test using Epi
Info 2000 (version 1.05, Center for Disease Control and
Prevention). p<0.05 was considered significant. The chi-
square test calculations for deviation from Hardy-Weinberg
equilibrium were performed at the web site http://www.hus-
dyr.kvl.dk/htm-/kc/genetik/2/kitest.htm (Prof. Knud Christensen).
RESULTS
The age (p=0.159) and sex (p=0.140) distribution of the
schizophrenic patients were similar to those of control pop-
ulation. The APOE genotypes and allele frequencies in the
schizophrenic patients and control population are given in
Table 1. In both groups the genotype distributions were in
Hardy-Weinberg equilibrium. The APOE genotypes in the
schizophrenic patients were distributed as follows:  2/ 3
(n=3, 5.0%),  3/ 3 (n=53, 88.3%),  3/ 4 (n=4, 6.7%).
There were significant differences in the distribution of APOE
genotypes between the two groups (p=0.044). APOE allele
frequencies of  2,  3, and  4 were 0.025, 0.942, and 0.033
in schizophrenic patients and were 0.108, 0.808, and 0.083
in normal controls, respectively. The frequency of APOE 3
in schizophrenic patients was significantly higher than that
in controls (p=0.0017; 2=9.75; Odds ratio 3.83, 95% CI
1.48-10.3). In contrast, the frequencies of APOE 2 (p=
0.0096; 2=6.7; Odds ratio 0.21, 95% CI 0.05-0.82) and
4 (p=0.098; 2=2.73; Odds ratio 0.38, 95% CI 0.1-1.37)
in schizophrenic patients were lower than those in controls.
DISCUSSION
In this study, we found that the frequencies of two APOE
alleles were significantly different between the schizophrenic
patients and the controls. APOE 3 showed a significant
association with the schizophrenic patients, as compared
with the controls. In contrast, the frequency of APOE 2i n
the schizophrenic patients was significantly lower than that
in the controls. These findings are in agreement with only a
few reports on the APOE genotypes in patients with schizo-
phrenia (20, 21) and stand in contrast to most other reports
(13-19). Although the basis for this discrepancy is unclear,
there are several possible explanations for this discrepancy.
First, the APOE allele frequency is dependent on the ethnic
and genetic background of the population being examined
(24). Thus, variations in the frequencies of APOE alleles in
schizophrenic patients compared with controls may be attri-
butable to this factor. Second, the differences may have been
due to the clinical status of the patients. Our patients were
inpatients in closed wards and therefore might have had
more severe psychopathology than the average. Third, early
methods for the detection of APOE isoforms were based on
protein isoelectrofocusing (25). Later, APOE genotyping
based on PCR and HhaI digestion were introduced (26).
However, PCR-based assays are difficult to interpret because
the HhaI enzyme yields several small fragments, not all of
which are specific for the APOE genotypes. While most prior
reports examined APOE genotype by PCR and HhaI diges-
tion, our APOE genotyping was determined by reverse hy-
bridization-based line probe assay. Different APOE genotyp-
ing methods might have affected discrepant reports on the
frequencies of APOE genotypes and alleles. Finally, it is pos-
sible that random effects from the smaller sample size of our
Schizophrenic patients Control subjects
Genotype:
2/ 3 3 (5.0%) 11 (18.3%)
2/ 4 0 (0%) 2 (3.3%)
3/ 3 53 (88.3%) 40 (66.7%)
3/ 4 4 (6.7%) 6 (10.0%)
4/ 4 0 (0%) 1 (1.7%)
Allele:
2 3 (2.5%)  13 (10.8%)
3 113 (94.2%) 97 (80.8%)
4 4 (3.3%) 10 (8.3%)
Table 1. Comparison of apolipoprotein E genotypes and allele
frequencies between schizophrenic patients (n=60) and con-
trol subjects (n=60)Apolipoprotein E Genotype in Schizophrenic Patients 783
study would account for the difference.
The frequency of the APOE 4 was lower in patients with
schizophrenia, but this was not statistically significant (p=
0.098) and thus does not provide evidence of an association
between the APOE 4 allele and schizophrenia. This find-
ing is similar to those of other reports (14-18).
In conclusion, our results suggest that two APOE alleles,
2 and  3, seem to figure in the pathogenesis of schizo-
phrenic disorders. This correlation certainly needs further
study with a large number of patients. 
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